Publication | Open Access

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

MedicinePharmacologyGynecologyFixed-dose Rate GemcitabinePharmacotherapyAnti-cancer AgentCancer TreatmentSecond-line TherapyOncologyGynecology OncologyMetastatic Uterine Leiomyosarcoma